Skip to content
Sectors How it works Pricing Client stories

Insights

Companies Live signals Events Markets Trends Company lists
Log in
Platform Signal Tracker API Radar Book a 7-day Readout
Corcept Therapeutics logo — Pioneering the discovery and development of cortisol modulat...

Corcept Therapeutics

Pioneering the discovery and development of cortisol modulators.

Founded 1998 United States Redwood City, United States 798 employees Post-IPO Equity Total: $119.09M Biotechnology, Pharmaceutical

General Information

Company Name Corcept Therapeutics
Founded Year 1998
Location United States Redwood City, United States
Founders / Decision Makers
Team member
Employees 798
Industries Biotechnology, Pharmaceutical
Funding Stage Post-IPO Equity
Social

BounceWatch is an independent company data service, not affiliated with Corcept Therapeutics. To contact Corcept Therapeutics, visit corcept.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Corcept Therapeutics compare?

A PDF of Corcept Therapeutics and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Corcept Therapeutics soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Corcept Therapeutics

Corcept Therapeutics is a biopharmaceutical company that has been pioneering the discovery and development of cortisol modulators since its founding in 1998. The company's mission is to unlock the potential of cortisol and revolutionize the treatment of serious diseases. Over the last 25 years, Corcept Therapeutics has been at the forefront of research and development in the field of selective glucocorticoid receptor (GR) antagonists, which are molecules that alter GR and regulate cortisol levels. In 2012, the company achieved a significant milestone with the FDA approval of a groundbreaking cortisol receptor blocker, marking the first approved treatment for hypercortisolism (Cushing’s syndrome). Corcept Therapeutics has established global partnerships and collaborations to support its robust development programs, which include the development of over 500 GR antagonists for conditions spanning oncology, endocrine, and various metabolic disorders. The company's work is positioned to bring about a fundamental shift in the understanding and treatment of disease, representing a potential sea change in the field. As of 10 April 2012, Corcept Therapeutics received a $525.31K Post-IPO Equity investment. However, the specific investors behind this investment are not disclosed. With its innovative approach and strong focus on research and development, Corcept Therapeutics continues to drive advancements in the field of cortisol modulation, reflecting a commitment to embracing possibilities and making a meaningful impact in biotechnology and pharmaceutical industries.

Business keywords: pharmaceuticals, cortisol modulation, glucocorticoid receptors antagonists, FDA approval, treatment development, hypercortisolism, Cushing's syndrome, oncology, endocrine disorders, metabolic disorders, collaborations, global partnerships, scientific research, drug development

Funding Rounds & Investors (8)

View All
Funding Stage Amount Investors Lead Investors Date
Post IPO Equity $525.31K -
10 Apr 2012
Post IPO Equity $39.00M -
21 Jan 2011
Post IPO Equity $7.65M -
30 Apr 2010
Post IPO Equity $18.01M 3
Longitude Capital Alta Partners Sutter Hill Ventures
Longitude Capital, Alta Partners +1
30 Oct 2009
Post IPO Equity $10.10M 3
Alta Partners Sutter Hill Ventures paperboy ventures
Alta Partners, Sutter Hill Ventures +1
20 Aug 2007
Post IPO Equity $3.00M -
15 Nov 2006
Venture Round $12.80M -
01 Dec 2002
Venture Round $28.00M -
01 May 2001

Corcept Therapeutics Alternatives & Competitors

View All Alternatives
Corcept Therapeutics vs
Astex Pharmaceuticals
Astex Pharmaceuticals United Kingdom

Committed to the fight against cancer and CNS disorders

136 employees
Biotechnology, Health Care
Compare Corcept Therapeutics vs Astex Pharmaceuticals
Corcept Therapeutics vs
Soleno Therapeutics, Inc.
Soleno Therapeutics, Inc. United States

Inspired by patients and families around the world, we are advancing much needed therapies for rare...

Post-IPO Equity
88 employees
Biotechnology, Pharmaceutical
Compare Corcept Therapeutics vs Soleno Therapeutics, Inc.
Corcept Therapeutics vs
Azevan Pharmaceuticals
Azevan Pharmaceuticals

Innovative therapies for stress, mood, and behavior disorders

Venture round
5 employees
Biotechnology, Health Care
View all alternatives

FAQ About Corcept Therapeutics

Pioneering the discovery and development of cortisol modulators.
Corcept Therapeutics was founded in 1998.
Corcept Therapeutics is headquartered in Redwood City, United States.
Corcept Therapeutics operates in Biotechnology and Pharmaceutical. Its work centres on pharmaceuticals, cortisol modulation, glucocorticoid receptors antagonists and FDA approval.
Corcept Therapeutics has approximately 798 employees.
Corcept Therapeutics has completed 8 funding rounds, raising a total of $119.09M. The latest funding stage is Post-IPO Equity.
Top alternatives and competitors to Corcept Therapeutics include Astex Pharmaceuticals , Soleno Therapeutics, Inc., Azevan Pharmaceuticals, Zai Lab, Emalex Biosciences. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Corcept Therapeutics and Astex Pharmaceuticals are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Corcept Therapeutics, https://bouncewatch.com/company/corcept-therapeutics, updated 6 August 2026. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout